Preferred Label : KLH/NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine;
NCIt synonyms : NY-ESO-1/MART-1 Peptide/KLH-pulsed Dendritic Cell Vaccine; KLH/NY-ESO-1/Melan-A Peptide-pulsed DC Vaccine; KLH/NY-ESO-1/MART-1 Peptide-pulsed DC Vaccine;
NCIt definition : A cell-based cancer vaccine composed dendritic cells (DC) that were matured in the
presence of a synthetic complex comprised of polyinosinic-polycytidylic acid, poly-L-lysine
double-stranded RNA, and carboxymethylcellulose (poly-ICLC), and then pulsed with
peptides derived from the tumor-associated antigens (TAAs) cancer/testis antigen NY-ESO-1
and melanoma antigen recognized by T-cells (MART-1/Melan-A), which are linked to the
immunostimulant and carrier protein keyhole limpet hemocyanin (KLH), with potential
immunostimulatory and antineoplastic activities. Upon intradermal administration,
the KLH/NY-ESO-1/MART-1 peptide-pulsed DC vaccine stimulates the immune system to
mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing
tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal
testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma
cells. The adjuvant poly-ICLC, a ligand for toll-like receptor-3 (TLR-3), induces
the release of cytokines that may help boost the immune response against the TAAs.
KLH boosts the immune response against the TAA-expressing tumor cells.;
NCI Metathesaurus CUI : CL514432;
Origin ID : C131287;
UMLS CUI : C4330517;
Semantic type(s)
- concept_is_in_subset
- has_target
